MET and colorectal carcinoma: Notably, activation of the Met/HGF receptor axis is emerging as an important mechanism of resistance to drugs targeting oncogenic kinases in human cancers, including CRC, while concurrent inhibition of multiple RTKs in CRC cells seems to offer better therapeutic effects than targeting a specific RTK [53-60].